Immunogenicity of poxvirus-based vaccines against Nipah virus

Nipah virus (NiV), an emerging zoonotic pathogen in Southeast Asia, is transmitted from Pteropus species of fruit bats to a wide range of species, including humans, pigs, horses, dogs, and cats. NiV has killed millions of animals and caused highly fatal human outbreaks since no vaccine is commercially available. This study characterized the immunogenicity and safety of poxvirus-based Nipah vaccines that can be used in humans and species responsible for NiV transmission. Mice were vaccinated with modified vaccinia Ankara (MVA) and raccoon pox (RCN) viral vectors expressing the NiV fusion (F) and glycoprotein (G) proteins subcutaneously (SC) and intranasally (IN). Importantly, both vaccines did not induce significant weight loss or clinical signs of disease while generating high circulating neutralizing antibodies and lung-specific IgG and IgA responses. The MVA vaccine saw high phenotypic expression of effector and tissue resident memory CD8alpha(+) T cells in lungs and splenocytes along with the expression of central memory CD8alpha(+) T cells in lungs. The RCN vaccine generated effector memory (SC) and tissue resident (IN) CD8alpha(+) T cells in splenocytes and tissue resident (IN) CD8alpha(+) T cells in lung cells. These findings support MVA-FG and RCN-FG viral vectors as promising vaccine candidates to protect humans, domestic animals, and wildlife from fatal disease outcomes and to reduce the global threat of NiV.

Automated summary

This study characterized the immunogenicity and safety of poxvirus-based Nipah vaccines in mice. The vaccines induced high levels of neutralizing antibodies and specific immune responses in the lungs. The findings support the use of these vaccines as promising candidates to protect humans and animals from Nipah virus.